OncoSil Medical Limited (ASX:OSL)

Australia · Delayed Price · Currency is AUD

0.6500

-0.0050 (-0.76%)

Feb 26, 2026, 3:47 PM AEST

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Device development for new medical treatments	1.54M	1.57M	1.47M	1.06M	1.30M
Device development for new medical treatments Growth	-1.92%	6.68%	38.00%	-18.10%	-53.02%
Total	1.54M	1.57M	1.47M	1.06M	1.30M
Total Growth	-1.92%	6.68%	38.00%	-18.10%	-53.02%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Australia	15.00K	60.00K	-	-	-
Australia Growth	-75.00%	-	-	-	-
Europe	869.56K	456.63K	111.79K	-	-
Europe Growth	90.43%	308.48%	-	-	-
Middle East	286.23K	-	-	-	-
APAC (Australia and New Zealand)	-	-	255.89K	231.79K	213.07K
APAC (Australia and New Zealand) Growth	-	-	10.40%	8.79%	-
Total	1.17M	516.63K	367.68K	231.79K	213.07K
Total Growth	126.62%	40.51%	58.63%	8.79%	-

Source: S&P Global Market Intelligence.